Amgen’s R&D group has been focusing considerable attention on its development of AMG 420 — a bispecific T-cell engager, or BiTE, in brand name parlance — that it believes can point them to a competitive position with the BCMA CAR-Ts now angling for first-mover advantage, and likely better than an antibody-drug conjugate. They came to San Diego with a first look at the Phase I data that include a high rate of response for one dose that could capture some support.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.Free Subscription